Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 Oct 26;20(1):608.
doi: 10.1186/s13063-019-3655-2.

A randomized controlled trial comparing lithium plus valproic acid versus lithium plus carbamazepine in young patients with type 1 bipolar disorder: the LICAVAL study

Giovani Missio  1 , Doris Hupfeld Moreno  2 , Frederico Navas Demetrio  2 , Marcio Gerhardt Soeiro-de-Souza  2 , Fernando Dos Santos Fernandes  2 , Vivian Boschesi Barros  3 , Ricardo Alberto Moreno  2
Affiliations
Randomized Controlled Trial

A randomized controlled trial comparing lithium plus valproic acid versus lithium plus carbamazepine in young patients with type 1 bipolar disorder: the LICAVAL study

Giovani Missio et al. Trials. .

Abstract

Background: Treatment of bipolar disorder (BD) usually requires drug combinations. Combinations of lithium plus valproic acid (Li/VPA) and lithium plus carbamazepine (Li/CBZ) are used in clinical practice but were not previously compared in a head-to-head trial.

Objective: The objective of this trial was to compare the efficacy and tolerability of Li/VPA versus Li/CBZ in treating type 1 BD in any phase of illness in young individuals.

Methods: LICAVAL was a randomized, unicenter, open-label, parallel-group trial that was conducted from January 2009 to December 2012 in a tertiary hospital in São Paulo, Brazil. Participants were between 18 and 35 years old and were followed up for 2 years. Our primary outcome was the number of participants achieving/maintaining response and remission during the acute and maintenance phases of BD treatment, respectively. Other outcomes assessed were symptom severity and adverse events throughout the study. In the analysis of the primary outcome, we compared groups by using a two-way repeated measures analysis of variance and estimated effect sizes by using Cohen's d.

Results: Of our 64 participants, 36 were allocated to Li/VPA and 28 to Li/CBZ. Our sample was composed predominantly of females (66.6%) and the average age was 27.8 years. A total of 27 (45.0%) participants had depression, 17 (28.3%) had mania/hypomania, and 16 (26.7%) had a mixed state. We found no between-group differences in CGI-BP (Clinical Global Impression Scale modified for use in bipolar disorder) scores (P = 0.326) or in any other outcome. Side effects differed significantly between groups only in the first week of treatment (P = 0.021), and there were more side effects in the Li/VPA group. Also, the Li/VPA group gained weight (+2.1 kg) whereas the Li/CBZ group presented slight weight loss (-0.2 kg).

Conclusion: Our study suggests that Li/VPA and Li/CBZ have similar efficacy and tolerability in BD but that Li/CBZ might have metabolic advantages in the long term.

Trial registration: ClinicalTrials.gov identifier: NCT00976794 . Registered on September 9, 2009.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Consolidated Standards for Reporting of Trials (CONSORT) flow diagram
Fig. 2
Fig. 2
Mean Clinical Global Impression Scale (CGI) scores per group at baseline and after 8 weeks in the LICAVAL study
Fig. 3
Fig. 3
Hamilton Depression Rating Scale and Young Mania Rating Scale - scores per group at baseline and after 8 weeks in the LICAVAL study
Fig. 4
Fig. 4
Cumulative survival per group in the LICAVAL study
See this image and copyright information in PMC

References

    1. Berk M. Neuroprogression: Pathways to progressive brain changes in bipolar disorder. Int J Neuropsychopharmacol. 2009;12:441–445. doi: 10.1017/S1461145708009498. - DOI - PubMed
    1. Fornaro M, De Berardis D, Koshy AS, Perna G, Valchera A, Vancampfort D, et al. Prevalence and clinical features associated with bipolar disorder polypharmacy: A systematic review. Neuropsychiatr Dis Treat. 2016;12:719. doi: 10.2147/NDT.S100846. - DOI - PMC - PubMed
    1. Grande I, de Arce R, Jiménez-Arriero MA, Lorenzo FGI, Valverde JIF, Balanzá-Martínez V, et al. Patterns of pharmacological maintenance treatment in a community mental health services bipolar disorder cohort study (SIN-DEPRES) Int J Neuropsychopharmacol. 2013;16:513–523. doi: 10.1017/S1461145712000405. - DOI - PubMed
    1. Keck JP, McElroy SL. Carbamazepine and valproate in the maintenance treatment of bipolar disorder. J Clin Psychiatry. 2002;63:13–17. - PubMed
    1. Granneman GR, Schneck DW, Cavanaugh JH, Witt GF. Pharmacokinetic interactions and side effects resulting from concomitant administration of lithium and divalproex sodium. J Clin Psychiatry. 1996;57:204–206. - PubMed

Publication types

MeSH terms

Associated data